Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 open-label study of ZL-1310 in solid tumors (neuroendocrine carcinoma)
CTR20251434Phase 2Active
- Sponsor
- Zai Lab
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of zocilurtatug pelitecan in neuroendocrine carcinoma (NEC), sponsored by Zai Lab. Started Apr 2025; status: active.
02
Drugs
zocilurtatug pelitecan
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on CTR20251434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251434.